Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Thermo Fisher Scientific technology used in new study of sepsis mortality

Thermo Fisher Scientific technology used in new study of sepsis mortality

26th April 2017

Thermo Fisher Scientific has announced the findings of a new study that has shed light on a potentially useful biomarker for mortality in patients with severe sepsis and septic shock.

The company's BRAHMS procalcitonin (PCT) assay has been used in the MOSES study to assess the risk for 28-day all-cause mortality among patients diagnosed with severe sepsis or septic shock in 13 US investigational sites.

It was shown that patients with a decrease in PCT less than or equal to 80 percent during the first four days following diagnosis had a twofold increased risk of death compared to those who experienced a decrease in PCT greater than 80 percent.

The study also found that a baseline PCT measurement greater than 2.0 ng/mL was an additional mortality risk factor when evaluating PCT measurements on subsequent days. It shows that this can be an effective approach to monitoring the progression of this condition.

Lonnie Shoff, president of the clinical diagnostics division at Thermo Fisher Scientific, said: "We look forward to continuing the conversation around the importance of sepsis awareness and the impact PCT can have in septic patient management."

Based on the findings of this study, Thermo Fisher Scientific has been granted expanded clearance in the US for this PCT biomarker assay to be used in sepsis risk assessment.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801835181-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.